Septal Rebound Stretch is a Strong Predictor of Outcome After Cardiac Resynchronization Therapy

Abstract Background Septal rebound stretch (SRSsept) is a distinctive characteristic of discoordination-related mechanical inefficiency. We assessed how intermediate- and long-term outcome after cardiac resynchronization therapy (CRT) relate to baseline SRSsept. Methods and Results A total of 101 pa...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiac failure 2012-05, Vol.18 (5), p.404-412
Main Authors: Leenders, Geert E., MD, De Boeck, Bart W.L., MD, PhD, Teske, Arco J., MD, PhD, Meine, Mathias, MD, PhD, Bogaard, Margot D., MD, Prinzen, Frits W., PhD, Doevendans, Pieter A., MD, PhD, Cramer, Maarten J., MD, PhD
Format: Article
Language:English
Subjects:
Aged
Cardiac Resynchronization Therapy
Cardiovascular
Echocardiography
Female
Follow-Up Studies
Heart failure
Heart Failure - diagnostic imaging
Heart Failure - physiopathology
Heart Failure - therapy
Heart Septum - diagnostic imaging
Heart Septum - physiopathology
Humans
Male
myocardial deformation
Prognosis
Retrospective Studies
Ventricular Remodeling - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Septal rebound stretch (SRSsept) is a distinctive characteristic of discoordination-related mechanical inefficiency. We assessed how intermediate- and long-term outcome after cardiac resynchronization therapy (CRT) relate to baseline SRSsept. Methods and Results A total of 101 patients (age 65 ± 11 years, 69 men, 18 New York Heart Association (NYHA) class IV, QRS 173 ± 23 ms) scheduled for CRT underwent clinical assessment, echocardiography, and brain-type natriuretic peptide (BNP) measurements before and 6.4 ± 2.3 months after CRT. Baseline SRSsept (all systolic stretch after initial shortening in the septum) was quantified by speckle tracking echocardiography. Primary composite end point was death, urgent cardiac transplantation, or left ventricular assist device implantation at the end of the study. Secondary end points were intermediate-term (6 months) response, quantified as decreases in left ventricular end-systolic volume (ΔLVESV) and BNP (ΔBNP). After a mean clinical follow-up of 15.6 ± 9.0 months; 23 patients had reached the primary end point. Baseline SRSsept (hazard ratio [HR] 0.742; 95% confidence intervals [CI] 0.601–0.916, P < .01]) was independently associated with a better outcome and NYHA class (HR 5.786: 95% CI 2.341–14.299, P < .001) with a worse outcome. Contrary to baseline NYHA class, baseline SRSsept was an independent predictor of both ΔLVESV (beta 0.53; P < .001) and ΔBNP (beta 0.29; P < .01). Intermediate-term ΔLVESV and ΔBNP were associated with a favorable long-term outcome. Conclusions SRSsept at baseline is a strong, independent predictor of long-term prognosis after CRT and of improvements in left ventricular remodeling and neurohormonal activation at intermediate term.
ISSN:1071-9164
1532-8414
DOI:10.1016/j.cardfail.2012.02.001